{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:31:41Z","timestamp":1788496301295,"version":"build-2803163510"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997,11,1]]},"abstract":"<jats:p>Background.\u2003X-linked hypophosphatemia (XLH) is characterized clinically by rickets and growth retardation. Conventional treatment of XLH with oral phosphate and vitamin D fails to normalize linear growth.<\/jats:p><jats:p>Objective.\u2003To determine the benefit and the potential side effects of recombinant human growth hormone (rhGH) therapy in patients with XLH.<\/jats:p><jats:p>Design and Methods.\u2003A randomized, double-blind, crossover study was performed throughout a 24-month period in five children with XLH, each patient serving as his own control. The effect of 12 months of rhGH therapy on height, mineral metabolism, glucose and lipid metabolism, hemoglobin, thyroid and parathyroid function, serum 1,25-(OH)2 vitamin D, osteocalcin, growth hormone, urinary calcium, phosphate, nephrocalcinosis, renal function, and bone density was compared with the effects of 12 months of placebo administration on the same parameters.<\/jats:p><jats:p>Results.\u2003The average age (mean \u00b1 SEM) of the patients at the start of the study was 5.6 \u00b1 1.4 years. Growth hormone therapy improved the height standard deviation score (z-score) from a baseline of \u22122.66 \u00b1 0.21 to \u22122.02 \u00b1 0.25 and to \u22121.46 \u00b1 0.28, after 3 and 12 months, respectively. At the start of the control period the heightz-score was \u22122.27 \u00b1 0.30 compared with \u22122.22 \u00b1 0.16 after 12 months of placebo administration. The growth velocity standard deviation score was \u22121.90 \u00b1 0.40 during the 12 months of placebo administration and +4.04 \u00b1 1.50 during the 12 months of rhGH therapy. An increase in serum phosphate from 0.88 \u00b1 0.07 mmol\/L to 1.17 \u00b1 0.14 mmol\/L and tubular maximum for phosphate reabsorption (TmP\/GFR) from 2.12 \u00b1 0.15 to 3.41 \u00b1 0.25 mg\/dL, was observed after 3 months of rhGH therapy. However, both serum phosphate and TmP\/GFR were unchanged from baseline after 6, 9, and 12 months of rhGH therapy. Neither serum phosphate nor TmP\/GFR changed from baseline during the placebo administration. Insulin-like growth factor 1 (IGF-1) increased from 114 \u00b1 25 to 354 \u00b1 51 ng\/mL after 12 months of rhGH therapy. Despite the increase in IGF-1 after rhGH therapy, the value did not exceed normal serum concentration. IGF-1 did not change from baseline after 12 months of placebo administration. Neither therapy with rhGH nor with placebo had an effect on glucose and lipid metabolism, hemoglobin, thyroid and parathyroid function, serum 1,25-(OH)2 vitamin D, alkaline phosphatase, osteocalcin, urinary calcium excretion, the grade of nephrocalcinosis, glomerular filtration rate, or urinary albumin excretion. Twelve months of rhGH therapy increased bone mass and width but not density. Twelve months of placebo administration had no effect on bone mass, width, or density.<\/jats:p><jats:p>Conclusion.\u2003Patients with XLH have an improvement in linear growth and a transient increase in serum phosphate attributable to a transient decrease in urinary phosphate excretion when treated with rhGH.<\/jats:p>","DOI":"10.1542\/peds.100.5.879","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:40:17Z","timestamp":1092440417000},"page":"879-884","source":"Crossref","is-referenced-by-count":47,"title":["The Effect of Recombinant Human Growth Hormone in Children With X-Linked Hypophosphatemia"],"prefix":"10.1542","volume":"100","author":[{"given":"Mouin G.","family":"Seikaly","sequence":"first","affiliation":[{"name":"From the University of Texas Southwestern Medical Center and the"},{"name":"Texas Scottish Rite Hospital for Children, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Brown","sequence":"additional","affiliation":[{"name":"Texas Scottish Rite Hospital for Children, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baum","sequence":"additional","affiliation":[{"name":"From the University of Texas Southwestern Medical Center and the"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[1997,11,1]]},"reference":[{"key":"2021121006431649900_B1"},{"key":"2021121006431649900_B2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1172\/JCI110912","article-title":"Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets.","volume":"71","author":"Insogna","year":"1983","journal-title":"J Clin Invest."},{"key":"2021121006431649900_B3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1172\/JCI109930","article-title":"Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.","volume":"66","author":"Drezner","year":"1980","journal-title":"J Clin Invest."},{"key":"2021121006431649900_B4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1542\/peds.94.4.478","article-title":"The effect of phosphate supplementation on linear growth in children with X-linked hypophosphatemia.","volume":"94","author":"Seikaly","year":"1994","journal-title":"Pediatrics."},{"key":"2021121006431649900_B5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets.","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med."},{"key":"2021121006431649900_B6","first-page":"91","article-title":"Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia.","volume":"97","author":"Seikaly","year":"1996","journal-title":"Pediatrics."},{"key":"2021121006431649900_B7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00862524","article-title":"Regulation of renal phosphate reabsorption during development: implications from a new model of growth hormone deficiency.","volume":"4","author":"Haramati","year":"1990","journal-title":"Pediatr Nephrol."},{"key":"2021121006431649900_B8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000167592","article-title":"Increase in renal plasma flow and glomerular filtration rate during growth hormone treatment may be mediated by insulin-like growth factor I.","volume":"8","author":"Hirschberg","year":"1988","journal-title":"Am J Nephrol."},{"key":"2021121006431649900_B9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/endo-123-3-1225","article-title":"Dietary phosphorus and 1,25-dihydroxyvitamin D metabolism: influence of insulin-like growth factor I.","volume":"123","author":"Halloran","year":"1988","journal-title":"Endocrinology."},{"key":"2021121006431649900_B10","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1073\/pnas.86.8.2868","article-title":"Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects.","volume":"85","author":"Guler","year":"1989","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021121006431649900_B11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1172\/JCI115312","article-title":"Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport.","volume":"88","author":"Quigley","year":"1991","journal-title":"J Clin Invest."},{"key":"2021121006431649900_B12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/BF00868733","article-title":"Stimulation of growth hormone secretion in children with X-linked hypophosphatemia.","volume":"9","author":"Seikaly","year":"1995","journal-title":"Pediatr Nephrol."},{"key":"2021121006431649900_B13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1210\/jcem-69-2-253","article-title":"Growth hormone treatment oF children with short stature increases insulin secretion but does not in impair glucose disposal.","volume":"69","author":"Walker","year":"1989","journal-title":"Clin Endocrinol Metab."},{"key":"2021121006431649900_B14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF00863432","article-title":"125 I-iothalamate clearance in children. A simple method to measure glomerular filtration.","volume":"10","author":"Bajaj","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"2021121006431649900_B15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2214\/ajr.146.6.1253","article-title":"Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression.","volume":"146","author":"Patriquin","year":"1986","journal-title":"Am J Roentgenol."},{"key":"2021121006431649900_B16"},{"key":"2021121006431649900_B17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000184216","article-title":"Direct measurement of TP\/GFR: a simple and reliable parameter of renal phosphate handling.","volume":"44","author":"Stark","year":"1986","journal-title":"Nephron."},{"key":"2021121006431649900_B18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0026-0495(64)90072-1","article-title":"Studies on vitamin D-resistant rickets: effects of human growth hormone.","volume":"13","author":"Gershberg","year":"1964","journal-title":"Metabolism."},{"key":"2021121006431649900_B19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/BF03349633","article-title":"Growth hormone therapy in a poorly growing child with hypophosphatemic rickets.","volume":"13","author":"Lanes","year":"1990","journal-title":"J Endocrinol Invest."},{"key":"2021121006431649900_B20","first-page":"1165","article-title":"Growth hormone therapy in hypophosphatemic rickets.","volume":"145","author":"Wilson","year":"1991","journal-title":"Am J Dis Child."},{"key":"2021121006431649900_B21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-3476(95)70070-6","article-title":"Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density.","volume":"127","author":"Saggese","year":"1995","journal-title":"J Pediatr."},{"key":"2021121006431649900_B22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/BF02079060","article-title":"Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphatemia.","volume":"154","author":"Haffner Dieter, Wuhl E, Blum W, Schaefer F, Mehls O","year":"1995","journal-title":"Eur J Pediatr."},{"key":"2021121006431649900_B23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.1992.tb12275.x","article-title":"Reference values for radial bone width and mineral content using single photon absorptiometry in healthy children aged 4 to 10 years.","volume":"81","author":"Bishop","year":"1992","journal-title":"Acta Paediatr"},{"key":"2021121006431649900_B24","first-page":"398","article-title":"Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin-like growth factor-1.","volume":"131","author":"Doi","year":"1988","journal-title":"Am J Pathol."},{"key":"2021121006431649900_B25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ki.1987.50","article-title":"Microalbuminuria as a predictor of clinical diabetic nephropathy.","volume":"31","author":"Mogensen","year":"1987","journal-title":"Kidney Int."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/100\/5\/879\/890025\/pe119700879o.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/100\/5\/879\/890025\/pe119700879o.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:31:08Z","timestamp":1682746268000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/100\/5\/879\/64607\/The-Effect-of-Recombinant-Human-Growth-Hormone-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,11,1]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[1997,11,1]]},"published-print":{"date-parts":[[1997,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.100.5.879","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[1997,11,1]]}}}